Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2012 1
2015 2
2016 3
2017 1
2018 1
2019 5
2020 5
2021 3
2022 1
2023 3
2024 19
2025 30
2026 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators. Perkovic V, et al. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24. N Engl J Med. 2024. PMID: 38785209 Clinical Trial.
BACKGROUND: Patients with type 2 diabetes and chronic kidney disease are at high risk for kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would mitigate these risks is unknown. ...CONCLUSIONS: Semaglutide reduced the risk …
BACKGROUND: Patients with type 2 diabetes and chronic kidney disease are at high risk for kidney failure, cardiovascula …
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, Charytan DM, Hadjadj S, Gillard P, Górriz JL, Idorn T, Ji L, Mahaffey KW, Perkovic V, Rasmussen S, Schmieder RE, Pratley RE, Tuttle KR. Mann JFE, et al. Nat Med. 2024 Oct;30(10):2849-2856. doi: 10.1038/s41591-024-03133-0. Epub 2024 Jun 24. Nat Med. 2024. PMID: 38914124 Free PMC article. Clinical Trial.
People with type 2 diabetes and chronic kidney disease have a high risk for kidney failure and cardiovascular (CV) complications. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors (SGLT2i) inde …
People with type 2 diabetes and chronic kidney disease have a high risk for kidney failure and cardiovascular (CV) comp …
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL, Idorn T, Lawson J, Mahaffey KW, Mann JFE, Mersebach H, Perkovic V, Tuttle K, Pratley R. Rossing P, et al. Nephrol Dial Transplant. 2023 Aug 31;38(9):2041-2051. doi: 10.1093/ndt/gfad009. Nephrol Dial Transplant. 2023. PMID: 36651820 Free PMC article.
BACKGROUND: Chronic kidney disease (CKD) is a common complication of type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control and lower body weight in people with T2D, and some reduce the risk …
BACKGROUND: Chronic kidney disease (CKD) is a common complication of type 2 diabetes (T2D). Glucagon-like pep …
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
Pratley RE, Tuttle KR, Rossing P, Rasmussen S, Perkovic V, Nielsen OW, Mann JFE, MacIsaac RJ, Kosiborod MN, Kamenov Z, Idorn T, Hansen MB, Hadjadj S, Bakris G, Baeres FMM, Mahaffey KW; FLOW Trial Committees and Investigators. Pratley RE, et al. J Am Coll Cardiol. 2024 Oct 22;84(17):1615-1628. doi: 10.1016/j.jacc.2024.08.004. Epub 2024 Aug 30. J Am Coll Cardiol. 2024. PMID: 39217553 Free article. Clinical Trial.
The FLOW (Research Study To See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease), which enrolled participants with T2D and CKD, demonstrated that semaglutide, a glucagon-like peptide- …
The FLOW (Research Study To See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney …
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity.
Abasheva D, Ortiz A, Fernandez-Fernandez B. Abasheva D, et al. Clin Kidney J. 2024 Nov 22;17(Suppl 2):19-35. doi: 10.1093/ckj/sfae296. eCollection 2024 Dec. Clin Kidney J. 2024. PMID: 39583142 Free PMC article.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as game-changers across the cardiovascular-kidney-metabolic (CKM) spectrum: overweight/obesity, type 2 diabetes mellitus (T2DM) and associated chronic kidney …
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as game-changers across the car …
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application.
Bae JH. Bae JH. Diabetes Metab J. 2025 May;49(3):386-402. doi: 10.4093/dmj.2025.0220. Epub 2025 May 1. Diabetes Metab J. 2025. PMID: 40367988 Free PMC article. Review.
Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease and significantly increases cardiovascular risk and mortality. ...The emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide …
Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease and significantly increases cardiov …
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.
Mahaffey KW, Tuttle KR, Arici M, Baeres FMM, Bakris G, Charytan DM, Cherney DZI, Chernin G, Correa-Rotter R, Gumprecht J, Idorn T, Pugliese G, Rasmussen IKB, Rasmussen S, Rossing P, Sokareva E, Mann JFE, Perkovic V, Pratley R. Mahaffey KW, et al. Eur Heart J. 2025 Mar 24;46(12):1096-1108. doi: 10.1093/eurheartj/ehae613. Eur Heart J. 2025. PMID: 39211948 Free PMC article. Clinical Trial.
BACKGROUND AND AIMS: In the FLOW trial, semaglutide reduced the risks of kidney and cardiovascular (CV) outcomes and death in participants with type 2 diabetes and chronic kidney disease (CKD). ...CKD was categorized by estimated glomerular filtration …
BACKGROUND AND AIMS: In the FLOW trial, semaglutide reduced the risks of kidney and cardiovascular (CV) outcomes and death in …
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.
Lee MMY, Sattar N, Pop-Busui R, Deanfield J, Emerson SS, Inzucchi SE, Mann JFE, Marx N, Mulvagh SL, Poulter NR, Badve SV, Pratley RE, Perkovic V, Buse JB, McGuire DK; SOUL Trial Investigators. Lee MMY, et al. Diabetes Care. 2025 May 1;48(5):846-859. doi: 10.2337/dc25-0241. Diabetes Care. 2025. PMID: 40156846
BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce the incidence of major adverse cardiovascular events (MACE) in type 2 diabetes (T2D), although whether benefits extend to both subcutaneous and oral formulations remains unclear. .. …
BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce the incidence of major adverse cardiovasc …
Glucagon-like peptide-1 receptor agonists and kidney outcomes.
MacIsaac RJ, Trevella P, Ekinci EI. MacIsaac RJ, et al. J Diabetes. 2024 Oct;16(10):e13609. doi: 10.1111/1753-0407.13609. J Diabetes. 2024. PMID: 39364792 Free PMC article. Review.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). ...Despite these promising findings, the …
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained increasing attention for their potential benefi …
Mechanisms of diabetic kidney disease and established and emerging treatments.
Martinez Leon V, Hilburg R, Susztak K. Martinez Leon V, et al. Nat Rev Endocrinol. 2026 Jan;22(1):21-35. doi: 10.1038/s41574-025-01171-3. Epub 2025 Sep 11. Nat Rev Endocrinol. 2026. PMID: 40935879 Review.
Kidney disease is one of the leading causes of mortality in persons with diabetes mellitus. ...Glucagon-like peptide 1 receptor agonists reduce albuminuria and preserve estimated glomerular filtration rate, as shown most recently in the …
Kidney disease is one of the leading causes of mortality in persons with diabetes mellitus. ...Glucagon-like …
81 results